Get started
Author

Juliana Maynard

Observed name: Maynard, Juliana
ORCID: 0000-0003-1636-6595
Observed ORCID: 0000-0003-1636-6595
OpenAlex ID: A5006565850
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2012 · Barry R. Davies, Hannah Greenwood, et al. · Molecular Cancer Therapeutics · 502
Micro-CT Imaging of Tumor Angiogenesis
2013 · Josef Ehling, Benjamin Theek, et al. · American Journal Of Pathology · 157
PDF
Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues
2020 · Nicola Ingram, Laura E. McVeigh, et al. · Theranostics · 68
PDF
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
2018 · James T. Lynch, Urszula M. Polanska, et al. · Molecular Cancer Therapeutics · 29
High-resolution 3D visualization of nanomedicine distribution in tumors
2019 · Jennifer I. Moss, Hervé Barjat, et al. · Theranostics · 21
PDF
Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055
2013 · Heather G. Keen, Sally-Ann Ricketts, et al. · Molecular Imaging and Biology · 21
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
2016 · Juliana Maynard, Sally-Ann Emmas, et al. · EJNMMI Research · 18
PDF
2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363
2013 · Juliana Maynard, Sally-Ann Ricketts, et al. · Molecular Imaging and Biology · 18
The Opportunities and Use of Imaging to Measure Target Engagement
2019 · Juliana Maynard, Philippa Hart · SLAS DISCOVERY · 12
PDF
The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor
2017 · Juliana Maynard, Sally-Ann Emmas, et al. · PLoS ONE · 8
PDF
A longitudinal study assessing lens thickness changes in the eye of the growing beagle using ultrasound scanning: relevance to age of dogs in regulatory toxicology studies
2014 · Juliana Maynard, Angela Sykes, et al. · Journal of Applied Toxicology · 2
PET in the characterization of immune diseases and development of therapeutics
2025 · Natasha Patel, Mats Bergstrom, et al. · Oxford Open Immunology · 1
PDF
Abstract 5098: A mouse DLL4 cross-reactive variant of MEDI0639 disrupts functional vessel formation and inhibits tumor growth in preclinical models.
2013 · Song H. Cho, David W. Jenkins, et al. · Cancer Research · 1
Abstract 4633: Theranostic evaluation of 68Ga-PMSA, 177Lu PSMA therapy, and biomarker guided immunotherapy and DDR inhibitor combinations in LNCaP prostate cancer xenografts
2026 · Juliana Maynard, Anita Liu, et al. · Cancer Research
Abstract 7370: End-to-end in vitro and in vivo evaluation of radiopharmaceuticals in patient-derived models
2026 · Anita Liu, Bryan Miller, et al. · Cancer Research
Abstract 1827: Investigating the efficacy of 177-Lu therapeutics in a series of castrate resistant prostate cancer PDX models
2025 · Stefano Cairo, Benedetta Arno, et al. · Cancer Research
Imaging Mutant Huntingtin Aggregates using [18F]CHDI-650 PET in a preclinical model of Huntington’s disease
2024 · Michael Fairclough, Dhifaf Jasim, et al. · The PET is wonderful journal.
PDF
Supplementary Table 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
Supplementary Figure Legends 1-5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
PDF
Supplementary Figure 3 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
PDF
Supplementary Figure 2 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
Supplementary Figure 4 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
PDF
Supplementary Figure 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
PDF
Data from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023 · Barry R. Davies, Hannah Greenwood, et al.
Works count: 38
Citation count: 858
H-index: 9
I10-index: 9
Year
Topic
Type